Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.
2019-02-14 | News
International experts cooperating with the FDA have confirmed the efficacy and safety of eskatemine in treatment of unipolar, treatment-resistant depression, which might become the first cutting edge therapy for patients since the last innovation introduced 35 years ago. Celon Pharma develops this substance in two indications and is currently conducting phase II clinical trials. OnRead more »
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
Celon Pharma at WSE
People are the key to the success of all projects. We know this well and we would also like you to learn this first hand. As a Celon Pharma S.A. employee, you will be provided with an attractive salary, in-depth training and an incentive system. What is equally important, you will have the satisfaction of working with modern and essential drugs which save and extend human life.